Assess whether scientific advice should be sought before the next trial

SITUATION A mid-size sponsor after a complete response letter has biosimilar analytical similarity report in hand following a CMO 483 that maps to the NDA CMC module. Regulatory-affairs lead must determine whether scientific advice should be sought before the next trial for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Regulatory-affairs lead can defend Proceed under protocol from biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge. 2. Regulatory-affairs lead cannot defend Proceed under protocol from biosimilar analytical similarity report; Pause the pathway is what the extract actually supports after a CMO 483 that maps to the NDA CMC module. 3. A CMO 483 that maps to the NDA CMC module never reached the population in biosimilar analytical similarity report — reopen intake, do not close scientific advice should be. 4. Two facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module conflict for regulatory-affairs lead; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Check whether biosimilar analytical similarity report supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move scientific advice should be for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for regulatory-affairs lead in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in biosimilar analytical similarity report, then the action for regulatory-affairs lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Owner and next date for regulatory-affairs lead in a mid-size sponsor after a complete response letter - What changes scientific advice should be if a CMO 483 that maps to the NDA CMC module is later withdrawn